Drug Profile
Research programme: myeloproliferative disorders therapeutics - Incyte/Syros
Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Incyte Corporation; Syros Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myeloproliferative disorders
Most Recent Events
- 31 Dec 2023 Discontinued for Myeloproliferative disorders in USA (unspecified route) before December 2023
- 28 Feb 2022 No recent reports of development identified for research development in Myeloproliferative disorders in USA
- 08 Jan 2018 Incyte Corporation and and Syros Pharmaceuticals agree to develop myeloproliferative disorder therapeutics in USA